The following video is from Friday's Motley Fool Money roundtable discussion, with host Chris Hill, and analysts Ron Gross, James Early, and Charly Travers.
First-quarter profits for Johnson & Johnson (JNJ -0.10%) came in higher than expected this week, with its consumer sales division resulting in $3.7 billion. With shares hitting an all-time high and rising more than 30% over the past year, Johnson & Johnson is acting like a growth stock. Is the future bright for this consumer giant?
Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now.
The relevant video segment can be found between 9:56 and 10:51.
For the full video of today's Motley Fool Money, click here.
